Wells Fargo & Company MN Has $1.67 Million Holdings in Avanos Medical, Inc. (NYSE:AVNS)

Wells Fargo & Company MN raised its holdings in Avanos Medical, Inc. (NYSE:AVNS) by 19.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 104,830 shares of the company’s stock after buying an additional 16,868 shares during the period. Wells Fargo & Company MN owned about 0.23% of Avanos Medical worth $1,669,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Barclays PLC raised its stake in Avanos Medical by 446.2% in the 3rd quarter. Barclays PLC now owns 96,194 shares of the company’s stock valued at $2,311,000 after acquiring an additional 78,583 shares during the period. Geode Capital Management LLC increased its holdings in shares of Avanos Medical by 1.5% in the third quarter. Geode Capital Management LLC now owns 1,054,162 shares of the company’s stock valued at $25,337,000 after purchasing an additional 16,065 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Avanos Medical by 6.9% in the third quarter. JPMorgan Chase & Co. now owns 69,571 shares of the company’s stock valued at $1,672,000 after purchasing an additional 4,472 shares during the period. Tributary Capital Management LLC lifted its stake in shares of Avanos Medical by 38.1% during the 4th quarter. Tributary Capital Management LLC now owns 893,008 shares of the company’s stock worth $14,217,000 after buying an additional 246,379 shares during the last quarter. Finally, Empowered Funds LLC boosted its holdings in shares of Avanos Medical by 141.3% during the 4th quarter. Empowered Funds LLC now owns 153,834 shares of the company’s stock worth $2,449,000 after buying an additional 90,091 shares during the period. 95.17% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Avanos Medical

In other news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares of the company’s stock, valued at approximately $1,251,216.75. This represents a 7.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.64% of the company’s stock.

Avanos Medical Stock Performance

Shares of NYSE AVNS opened at $12.35 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. The firm has a market cap of $568.14 million, a price-to-earnings ratio of 36.32 and a beta of 1.15. The stock’s fifty day moving average price is $14.00 and its two-hundred day moving average price is $16.74. Avanos Medical, Inc. has a one year low of $11.84 and a one year high of $25.36.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The business had revenue of $179.60 million for the quarter, compared to the consensus estimate of $177.23 million. On average, equities analysts forecast that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Avanos Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, March 19th.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.